CROI

CROI
February 19-22, 2023
Seattle, Washington

Conference on Retroviruses and Opportunistic Infections 2023.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (19)

    Lenacapavir protects against rectal SHIV acquisition in macaque model

    • Author(s): Bekerman E
    • sunlenca
    • HIV / AIDS

    Week 52 subgroup efficacy of lenacapavir in heavily treatment-experienced PWH

    • Author(s): Onyema, O
    • sunlenca
    • HIV / AIDS

    Susceptibility screening to bnabs GS-5423 and GS-2872 in art-suppressed patients

    • Author(s): Selzer, L
    • bnab-combination-(gs-5423,-gs-2872)
    • HIV / AIDS

    Population PK analysis to guide dosing window following lenacapavir SC administration

    • Author(s): Shaik, N
    • sunlenca
    • HIV / AIDS

    Six-month outcome of F/TAF cobicistat-boosted darunavir in children 14 to <25kg

    • Author(s): Mujuru, H
    • vemlidy
    • HIV / AIDS

    Predictors of Hepatitis B treatment response in people with HIV/HBV coinfection

    • Author(s): Anchalee, A
    • biktarvy
    • HIV / AIDS

    Remdesivir Reduces Mortality in Immunocompromised Patients Hospitalized For COVID-19

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19

    Remdesivir Reduces Mortality in Hospitalized COVID-19 Patients Across Variant Eras

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19

    Heterologous Chad/Samrna SIV vaccine induces robust T cell responses in macaques

    • Author(s): Rappaport, A
    • gritstone-vaccine
    • HIV / AIDS

    Vesatolimod pharmacodynamic response is associated with time to HIV rebound

    • Author(s): Zhang, L
    • vestalimod-(gs-9620)
    • HIV / AIDS

    Antiviral activity of lenacapavir against HIV-2 isolates

    • Author(s): Smith, R
    • sunlenca
    • HIV / AIDS

    Lenacapavir with bnabs GS-5423 and GS-2872 dosed every 6 months in people with HIV

    • Author(s): Eron, J
    • sunlenca
    • HIV / AIDS

    Long-acting lenavapavir in a combination regimen for treatment naïve PWH: Week 80

    • Author(s): Hagins, D
    • sunlenca
    • HIV / AIDS

    SARS-CoV-2 Replicon System For The Phenotypic Evaluation of NSP Gene Substitutions

    • Author(s): Han, D
    • veklury
    • COVID-19

    Pharmacokinetics Inform Remdesivir Dosing for Patients With Severe Renal Impairment

    • Author(s): Humeniuk, R
    • veklury
    • COVID-19

    Remdesivir Retains Potent Activity Against SARS-CoV-2 Omicron Subvariants

    • Author(s): Hedskog, C
    • veklury
    • COVID-19

    Remdesivir Resistance Analyses From The PINETREE Study in Outpatients With COVID-19

    • Author(s): Rodriguez, L
    • veklury
    • COVID-19

    Remdesivir is Associated With Reduced Readmission After COVID-19 Hospitalization

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19

    8+ years pooled analysis: Adherence and HIV Incidence in 6000 Women on F/TDF for PrEP

    • Author(s): Marrazzo J
    • truvada-for-prep
    • HIV / AIDS